Wugen
wugen.comLocations
St. Louis, MO, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2018
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
Something looks off?Open jobs at Wugen
On-site & Remote
Salary